Galapagos - Winner 2010
The Belgian biotech company Galapagos has won the 2010 EUROPEAN BIOTECHNICA AWARD. Galapagos thus secures the lion's share of the prize money totalling 75,000 euros, which is offered every year in the competition staged by Deutsche Messe AG and its partners. The award celebrates innovative European companies from the biotechnology sector and the life sciences.
Based in the town of Mechelen, Belgium, Galapagos specializes in the research and development of anti-body and small molecular therapies for the treatment of cancer, diabetes, Alzheimer's disease, multiple sclerosis, rheumatoid arthritis and inflammatory diseases. The company currently has a product pipeline comprising six clinical, one preclinical and over 50 small molecule pre-clinical programs. "Galapagos shows a remarkable combination of scientific know-how in different fields and business success through cooperations with eight big pharmaceutical firms", as pointed out by Dr. Rolf G. Werner, deputy chair of the international panel of nine experts that judges the competition.
Galapagos is a medium-sized biotech company specialized in the research and development of anti-body and small molecular therapies with novel modes of action. The company is currently developing one of the biggest product pipelines in the biotechnology sector, with six clinical and over 50 preclinical programs devoted to small molecule research. Risk/reward sharing alliances with GlaxoSmithKline, Eli Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier mean that Galapagos is eligible to receive 3.3 billion in downstream milestone payments, plus royalties. The company's international headquarters is in Mechelen, Belgium. www.glpg.com
Addex Pharmaceuticals researches and develops allosteric modulators which can be used as therapeutic agents, in particular focusing on validated therapeutic targets in diseases affecting the central nervous system, as well as metabolism and inflammatory disorders. The company's product pipeline demonstrates the productivity and great potential of the unparalleled proprietary know-how of Addex Pharmaceuticals. Depending on the conclusion of the Phase I tests and regulatory approval, Phase II clinical trials will start in late 2010 in four indicators for two lead products which are used in therapy for Parkinson's disease and schizophrenia. A third product, which has good potential value as a therapy for chronic pain, is scheduled to enter Phase I testing towards the end of 2010. In addition, Merck & Co., Inc. has licensed rights to two pre-clinical products targeting Parkinson's disease and schizophrenia. Roche Venture Fund as well as SR-One, the venture capital fund of GlaxoSmithKline, have invested in Addex. www.addexpharma.com
Apeiron Biologics AG is a privately funded biotech company located in Vienna. In February 2010 the company licensed out its lead product at the time - APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapy used to treat acute respiratory distress syndrome (ARDS) and a whole number of other diseases - to GlaxoSmithKline in a milestone dependent agreement amounting to approx. 236 million euros. Alongside numerous innovative projects the company is also building a mature, low-risk project portfolio with the prime focus on biological/immunological cancer therapies. Apeiron currently has 15 employees at its central facility at the Vienna Campus Biocenter. www.apeiron-biologics.com
myBIOTECHNICA offers an array of planning aids for your trip to the show.
Save and organize the results of your website and database queries and coordinate your appointments from the comfort of your home or office.
Forgot your login data?
If you have forgotten your password, you can assign yourself a new one here:
Register now and take advantage of the numerous online services available for your personal profile, featuring planning aids for your trip to the show.
In order to use this service, you need to log in.
Please log in now or create a new user account.